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Abstract: Pegylated liposomal doxorubicin is a formulation of doxorubicin in which the 
molecule itself is packaged in a liposome made of various lipids with an outer coating of 
polyethylene glycol. Liposomal technology is being used in increasing amounts in the therapy 
of a variety of cancers, including ovarian cancers. This article reviews the mechanistic actions 
of this formulation, the Phase II and Phase III data that helped define the role of pegylated 
liposomal doxorubicin in recurrent ovarian cancer, as well as a discussion of some of the side-
effects and their management.
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Introduction
According to the American Cancer Society (2006), an estimated 20 180 new cases of 
ovarian cancer will be diagnosed in the US in 2006. Approximately 15 310 of these 
women will die of this disease. The vast majority will present with advanced disease 
and will require chemotherapy, and the majority of these will relapse. Currently, in the 
US, the initial treatment consists of maximal surgical debulking followed by carboplatin 
and taxane chemotherapy. When the disease recurs, the patient and physician are 
presented with a host of chemotherapy options. One drug that is increasingly being 
used is pegylated liposomal doxorubicin (DOXIL
® [US], Caelyx
® [outside US]; 
Tibotec Therapeutics, a division of Ortho Biotech Products, L.P., Bridgewater, NJ, 
USA. http://www.tibotec.com). 
Mechanism of action
Pegylated liposomal doxorubicin is one of a new class of drug formulations that 
is delivered in vesicles called liposomes. The doxorubicin molecules in pegylated 
liposomal doxorubicin are encapsulated in a bilayer sphere of lipids. This vesicle 
is then surrounded by a dense layer of polyethylene glycol (PEG), hence the name 
pegylated liposomal doxorubicin (Figure 1). The size of the liposomes, approximately 
100 nm, prevents them from entering tissues with tight capillary junctions, such as the 
heart and gastrointestinal tract, as well as selectively depositing the liposome into the 
tumor (Waterhouse et al 2001) (Figure 2). In contrast to normal vessels, the vessels 
of the tumor are tortuous, dilated, have morphologically abnormal endothelial cells, 
and are leaky due to large spaces between pericytes (Figure 3) (Jain 2005). These 
physical characteristics allow more extravasation of the vesicles into the tumor, thus 
encouraging more deposition of the chemotherapy agent into the tumor. The PEG 
coating on the liposome creates a hydrophilic layer around the liposome that buffers 
the liposome wall from the surrounding milieu. This decreases proteins from binding 
to the lipid bilayer. These proteins act as opsonins, attracting foreign particles that in 
Andrew e Green 
Peter G rose
Section of Gynecologic Oncology, 
Department of Obstetrics and 
Gynecology, Cleveland Clinic 
Cleveland, OH, USA
Correspondence: Peter G rose 
Section of Gynecologic Oncology, 
Department of Obstetrics and 
Gynecology, Cleveland Clinic,  
9500 euclid Avenue, A-81, Cleveland, 
OH 44195, USA 
Tel +1 216 444 1712 
Fax +1 216 444 8551 
email rosep@ccf.org
Pegylated liposomal doxorubicin in ovarian 
cancerinternational Journal of Nanomedicine 2006:1(3) 230
Green and rose
and returned to the circulation. In tumor tissue, however, 
there are no lymphatics. Therefore, when the liposome is 
deposited it remains for a longer time. This allows a higher 
dose of doxorubicin to be released in the tumor, and a lower 
dose in normal tissue (Gordon et al 2000). Collectively, there 
is preferential uptake and decreased clearance of the drug 
delivery system, increasing the exposure of the tumor to the 
drug. This was termed by Cattel et al (2003) as the enhanced 
permeation retention effect. 
Phase II single-agent studies
Table 1 summarizes the multiple Phase II trials of pegylated 
liposomal doxorubicin in recurrent ovarian cancer. In 1997 
Muggia et al (1997) reported 35 consecutive patients at 
2 institutions who had recurred following platinum- and 
paclitaxel-based chemotherapy. Patients were treated with 
pegylated liposomal doxorubicin at a dose of 50 mg/m
2 
every 21 days. There were 9 (25.5%) responses, including 
1 complete response. The median progression-free survival 
was 5.7 months and the median overall survival was 11 
months. Thirteen (37%) patients had a grade 3 or 4 toxicity, 
but were managed by decreasing the dose to 40 mg/m
2, or by 
lengthening the dosing interval to 4 or 5 weeks. 
In a subsequent Phase II study, Gordon et al (2000) 
evaluated 79 better-defined patients all of whom were 
platinum and taxane refractory. Eighty-five percent of the 
patients had received more than 2 prior chemotherapy 
regimens. These “doubly refractory” patients were treated 
Figure 1  Pegylated liposomal doxorubicin (PLD) molecule. reprinted with  
the permission of the Cleveland Clinic Foundation. 
Abbreviations: MPeG-DSPe, N-(carbonyl-methoxypolyethylene glycol 
2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt.
Figure 2  Scale drawing of the aforementioned (Figure 1) macule in cardiac 
tissue. reprinted with the permission of the Cleveland Clinic Foundation.
turn activate the mononuclear phagocytic cells. This leads 
to break down of the liposome and release of the drug. 
Therefore, the PEG coating on the liposome increases the 
longevity of the liposome.
When the liposome does leave the intravascular compart-
ment, in normal tissues it is cleared via the lymphatic system 
Figure 3  Pegylated liposomal doxorubicin (PLD) molecule in normal (left)  
and tumor (right) vessels. reprinted with the permission of the Cleveland  
Clinic Foundation.international Journal of Nanomedicine 2006:1(3) 231
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with 50 mg/m
2 of pegylated liposomal doxorubicin every 4 
weeks. Fourteen partial responses and 1 complete response 
were reported for an overall response rate of 16.9%. 
The median time to response was 15 weeks. The median 
progression-free survival for all patients treated in this study 
was 19.3 weeks (range 0.7–86 weeks). In addition, 36 patients 
(57%) were classified as having stable disease, and achieved 
a median progression-free survival of 21.9 weeks. This was 
one of the first studies to show that disease stabilization in 
recurrent ovarian cancer is of clinical benefit. All patients 
reported at least 1 adverse event, but the majority were 
grade 1 or 2. Asthenia and palmar-plantar erythrodysesthesia 
(PPE) were seen in 41.6%. Only 1 patient experienced any 
cardiac complications, and there were no treatment-related 
deaths. This study demonstrated that pegylated liposomal 
doxorubicin was useful in this drug-resistant setting, and 
associated with no life-threatening toxicities. 
In the same year, Markman et al (2000), with the 
intent to find a more tolerable dose of pegylated liposomal 
doxorubicin, published a Phase II trial of 40 mg/m
2. They 
evaluated 44 patients with platinum- and paclitaxel-refractory 
ovarian, peritoneal, and fallopian tube cancer. The patients 
received a median of 2 (range 1–12) treatments. There 
were 4 patients (8%) with evidence of a partial response 
or benefit, defined as decreasing symptoms and a decrease 
in CA-125 (cancer antigen 125). Another 8 (16%) were 
classified as stable disease and received more than 6 doses. 
There were 6 cases (12%) of grade 2 PPE, 4 (8%) grade 
2 mucosal toxicities, but no grade 3 toxicities. Six of the 
patients required dose reductions that were treatment-related. 
They concluded that in the setting of palliative therapy for 
refractory ovarian cancer, this dosing regimen presented an 
acceptable option for patients.
Campos et al (2001) published a retrospective study of 71 
patients with recurrent ovarian cancer who received 40 mg/m
2 
every 28 days. A partial response was seen in 16 patients 
(23%) and a complete response in 3 (4%) for an overall 
response rate of 27%. Additionally, there were 12 (17%) 
patients with stable disease, defined as <50% reduction in 
the sum of bidimensional measurements, a <50% reduction 
in CA-125, and no progression for 3 weeks. Surprisingly, 
among 51 platinum-resistant patients, there were 14 partial 
and 2 complete responses for an overall response rate of 35%, 
which was a slightly higher response rate than in the study 
overall. The median progression-free survival was 5.3 months 
(range 2.1–12.1). Also, Rose et al (2001) retrospectively 
compared 40 patients treated with pegylated liposomal 
doxorubicin at a dose of 50 mg/m
2 with 38 patients treated 
at a dose of 40 mg/m
2. Patients were treated with the higher 
dose until 1999 and a lower dose regimen afterward. No 
difference in progression-free survival was noted. However, 
dose reductions were required in 27% of the group in the 
higher dose and in none of the patients treated at the lower 
dose (Rose et al 2001).
Lorusso et al (2004) treated 37 patients in a Phase II study 
at a dose of 35 mg/m
2 every 3 weeks in an attempt to decrease 
the incidence of skin toxicity. Although patients were 
pretreated with a median of 2 other chemotherapy regimens, 
and 32.4% had received at least 4 different chemotherapy 
regimens, 20 (54%) remained platinum sensitive. All received 
at least 2 courses of the pegylated liposomal doxorubicin. 
While there were no complete responses, 5 patients had 
a partial response and 16 patients had stable disease. The 
median time to response was 12 weeks. There were 2 partial 
responses in the platinum-sensitive population and 3 in the 
platinum-resistant group. In the heavily pretreated population 
(>3 prior regimens) there was only 1 response among 17 
patients (5.8%). In contrast, 4 out of 20 patients who had 
received 1 or 2 prior treatment regimens responded (20%). 
Although not statistically significant, this suggests that using 
pegylated liposomal doxorubicin earlier in the course of 
recurrent disease is preferable. 
Table 1  Phase ii trials – single agent
Author  Year  Drug (dose)  n =  Responses (%)  Platinum resistant  Stable disease
Muggia   1997  PLD (50 mg/m
2) q 3 wks  35  9 (25.5%)  100%  Nr
Gordon  2000  PLD (50 mg/m
2) q 4 wks  79  13 (16.9%)  100%  36 (57%)
Markman  2000  PLD (40 mg/m
2) q 4 wks  44  4 (8%)  100%  8 (16%)
Campos   2001  PLD (40 mg/m
2) q 4 wks  72  19 (27%)  40%  Nr
rose   2001  PLD (50 mg/m
2) q 4 wks  37  5 (13.5%)  100%  18 (48.6%)
rose   2001  PLD (40 mg/m
2) q 4 wks  39  3 (7.7%)  100%  20 (51.3%
Lorusso  2004  PLD (35 mg/m
2) q 3 wks  37  5 (13%)  46%  18 (48%)
Arcuri  2004  PLD (50 mg/m
2) q 4 wks  20  7 (26.6%)  66%  Nr
wilailak  2004  PLD (40 mg/m
2) q 3 wks  14  3 (23%)  100%  Nr
Chou   2005  PLD (45 mg/m
2) q 4 wks  29  7 (23%)  100%  Nr
Abbreviations: Nr, not reported; PLD, pegylated liposomal doxorubicin.international Journal of Nanomedicine 2006:1(3) 232
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Arcuri (2006) reported on 30 patients who recurred 
following prior platinum-based chemotherapy and were 
treated with single-agent pegylated liposomal doxorubicin 
at 50 mg/m
2 every 28 days. There were 6 (20%) partial 
responses and 2 (6.6%) complete responses for an overall 
response rate of 26.6%. Among 23 patients defined as 
platinum resistant, only 2 (8.7%) responded. Again, the 
median time to response was 12 weeks. At this dose, a higher 
frequency of toxicities was noted, with a 23.3% incidence of 
grade 3 or 4 neutropenia. Grade 3 or 4 PPE was reported in 
10% of the patients and grade 3 or 4 mucositis also occurred 
in 10% of the patients. 
In smaller studies of single-agent pegylated liposomal 
doxorubicin in recurrent ovarian cancer, Wilailak and 
Linasmita (2004) at a dose of 40 mg/m
2 every 3 weeks and 
Chou et al (2005) at a dose of 45 mg/m
2 every 4 weeks both 
reported response rates of 23%. 
Randomized single-agent studies
There have been 2 randomized trials of pegylated liposomal 
doxorubicin in recurrent ovarian cancer (Table 2). Gordon 
et al (2001) reported on 474 patients randomized to either 
pegylated liposomal doxorubicin at 50 mg/m
2 every 4 weeks 
or topotecan 1.5 mg/m
2 daily for 5 days every 3 weeks. 
Response rates for pegylated liposomal doxorubicin and 
topotecan were 19.7% and 17%, respectively (p=0.390). At 
the time of the original publication only a trend in increased 
progression-free survival was noted in favor of the pegylated 
liposomal doxorubicin group (p=0.095). Although the study 
was not designed for subgroup analysis, among the platinum-
sensitive group there was a progression-free survival 
(p=0.037) and overall survival advantage (108 vs 71.1 weeks, 
p=0.008) in favor of the pegylated liposomal doxorubicin 
arm. In contrast, the platinum-resistant patients showed no 
survival advantage. The toxicity profiles between these two 
chemotherapy agents were quite different. Although nearly   
all patients reported at least 1 adverse event, there were more 
grade 4 events in the topotecan group (71% vs 17%). In the 
pegylated liposomal doxorubicin group there was a 49% 
incidence of PPE (22% grade 3 and 0.8% grade 4) and a 
40% incidence of stomatitis. In the topotecan group, >90% 
experienced hematologic toxicity and two thirds were grade 
3 or 4. Also of significance was that 3.8% (9 patients) of the 
topotecan group developed treatment-related sepsis, and 3 of 
these patients died as a result of it. There were no treatment-
related deaths in the pegylated liposomal doxorubicin group 
and these patients had fewer treatment modifications. There 
were a similar number of patients who withdrew from the 
study due to adverse events (43 in the pegylated liposomal 
doxorubicin group and 37 in the topotecan group). A long-
term follow up on this study was subsequently reported 
(Gordon et al 2004). At the time of this evaluation 87% 
(413) had died. There was a significant survival advantage 
for all patients entered on this study in favor of the pegylated 
liposomal doxorubicin arm (p=0.050), resulting in an 18% 
reduction in the risk of death, a difference of more than 3 
weeks. Among the patients with platinum-sensitive disease 
a more significant benefit was seen, resulting in a 30% 
reduction in death and a total survival of 107.9 vs 70.1 weeks. 
This is the first study to show a survival advantage between 
2 non-platinum agents. 
In a second randomized trial, O’Byrne et al (2002) studied 
214 patients randomized to either pegylated liposomal 
doxorubicin (50 mg/m
2) every 4 weeks or paclitaxel 175 mg/
m
2 every 3 weeks. The study was suspended due to poor 
accrual, as paclitaxel became incorporated into first-line 
therapy. A preliminary review of the data showed that there 
were no significant differences in response rates, progression-
free survival, or overall survival. The number of adverse 
events was similar.
Administration and side-effects 
Pegylated liposomal doxorubicin is associated with a number 
of adverse effects. The first adverse effect seen is an acute 
hypersensitivity reaction. This reaction is characterized 
by flushing, facial edema, headache, back pain, rigors, 
Table 2  randomized studies single-agent trials
Author  Year  Drug (dose)  n =  Survival advantage  Platinum  Side-effect 
          resistant  advantage
Gordon  2001    474     50%  Yes – PLD 
 
O’Byrne  2002  PLD (50 mg/m
2) q 4 wks   214  None  100%  none 
      vs paclitaxel 175 mg/m
2  
      q 3 wks
Abbreviations: PLD, pegylated liposomal doxorubicin.
PLD (50 mg/m
2) q 4 wks, 
vs topotecan 1.5 mg/m
2/d 
for 5 days q 3 weeks
Yes – PLD in both platinum 
sensitive and in the study 
overallinternational Journal of Nanomedicine 2006:1(3) 233
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hypotension, chest/throat tightness and dyspnea. This 
hypersensitivity reaction is seen in 6.8% of patients and 
usually occurs during the first administration (Uziely et al 
1995). This differs from the classic hypersensitity reactions, 
which occur only after previous exposure to the allergen. To 
overcome this reaction the initial administration of pegylated 
liposomal doxorubicin is given over 2 hours with pretreatment 
with diphenhydramine, dexamethasone, and famotidine. If 
no infusion reaction occurs, the subsequent doses can be 
given over 1 hour without pretreatment. If hypersensitivity 
is not seen initially, it will usually not be seen in subsequent 
administrations. If a hypersensitive reaction does occur, the 
reaction is managed by temporarily discontinuing the infusion 
until symptoms resolve. The infusion can then be restarted at 
25% of the original rate. This usually alleviates any further 
hypersensitivity. 
PPE and mucositis are the most common serious side-
effects of pegylated liposomal doxorubicin. Both are dose- 
and schedule-dependent. PPE, also referred to as hand-foot 
syndrome, although seen with other chemotherapy agents, 
is extremely common with liposomal therapy and can be 
very severe. Following administration, the liposomes tend 
to pool in the post-capillary venules where the liposome is 
degraded and the drug is released. Accumulation of liposomal 
doxorubicin can also be seen in areas of skin trauma, which 
may be subclinical. Subclinical skin trauma may occur as a 
result of tight-fitting clothing or shoes, intercourse, repetitive 
contact, or even recent surgical incisions. Symptoms usually 
present 14–21 days after the third cycle of therapy. The 
syndrome is characterized by a prodrome of paraesthesia of 
the extremities, usually occurring 3–5 days before cutaneous 
symptoms become identifiable. This can progresses to painful 
erythema and cracking of the palmar and plantar surfaces, 
followed by desquamation (Gordon et al 2001). Grade 3 or 
4 PPE is seen in 17.5% of patients with pegylated liposomal 
doxorubicin at a dose of 50 mg/m
2 every 4 weeks (Nagore et   
al 2000). The symptoms worsen with repeated doses, 
especially at higher doses and shortened dosing intervals. It 
is theorized that the accumulation in skin, and thus this side-
effect, is due to vascular permeability at contact–pressure 
points (Cattel et al 2003). While PPE cannot be prevented, 
its severity can be decreased with dose modification, either 
by decreasing the dose or lengthening the dosing interval. 
Dose modification often allows continued treatment without 
recurrence of PPE. In Lorusso’s (2004) study with a 
decreased dose of pegylated liposomal doxorubicin utilized 
(35 mg/m
2), there was a 21.6% incidence of PPE but it was 
grade 3 in severity in only 1 (2.8%) and no patient had grade 
4 toxicities. In a series of patients treated at 40 mg/m
2 (Kim 
et al 2005) there was only a 1% rate of grade 3 and no grade 
4 toxicities among 90 patients. There are preliminary data 
indicating that some drugs, including B6, lysine, topical 
dimethyl sulfoxid, and topical or systemic steroids may 
decrease the rate and/or severity of PPE; however, this has 
not been extensively studied. Drake et al (2004) reported a 
prospective study of 23 patients treated at a dose of 50 mg/
m
2. Nine patients (39%) developed grade 2–4 PPE. These 
symptoms were significantly decreased in 6 patients treated 
with oral dexamethasone 8 mg bid beginning 24 hours before 
the infusion. 
Mucositis is often a dose-limiting toxicity and can 
be seen after a single injection of high-dose pegylated 
liposomal doxorubicin as well as after numerous cycles. 
Its severity can also be modulated by altering the dosing 
regimen. Our regimen for mucositis prophylaxis includes 
L-lysine 500 mg tid (3 tabs tid) with the use of either or 
both of the following mouth washes when patients develop 
oral symptoms: benadryl, maalox, xylocaine, or tetracycline 
400 mg, hydrocortisone 110 mg, 30 mL nystatin, 240 mL 
chlor-trimeton 5 cc swish and spit qid.
In an effort to prevent PPE and mucositis a number 
of behavioral modifications have been utilized. Avoiding 
activities that increase blood flow or cause trauma to the skin 
or mucosal membranes, such as hot liquids, hot foods, hot 
baths, tight fitting clothes, bras, and shoes. Alternatively, ice 
packs to the hands and feet have been utilized to decrease 
blood flow. Unfortunately, the efficacy of these interventions 
has not been prospectively studied. 
Myelotoxicity is generally mild, and cumulative toxicity 
is not observed, indicating minimal damage to the marrow. 
Severe myelosuppression is so rare, Campos et al (2001) 
were able to treat 10 patients who had limited bone marrow 
reserve after failing high-dose therapy with peripheral stem 
cell support.
In contrast to free doxorubicin, cardiotoxicity has been 
shown to be extremely rare. In patients in whom there was 
an associated change in the status of the heart, often it 
was either not clinically significant and picked up only on 
screening echocardiograms, or it presented in patients with 
significantly compromised cardiac status. This was confirmed 
in a study of 509 breast cancer patients who were randomized 
to pegylated liposomal doxorubicin 50 mg/m
2 every 4 weeks 
or doxorubicin 60 mg/m
2 every 3 weeks (O’Brien et al 
2004). This study was designed as a non-inferiority study 
and showed equivalent efficacy. However, cardiotoxicity was 
significantly less with pegylated liposomal doxorubicin (p= international Journal of Nanomedicine 2006:1(3) 234
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<0.001, HR=3.16). Myelosuppression and alopecia were 
significantly improved as well. 
The dosing for pegylated liposomal doxorubicin and 
conventional doxorubicin are different (40–50 mg/m
2 every 
4 weeks vs 60–90 mg/m
2 every 3 weeks) (Rose 2004). 
Pegylated liposomal doxorubicin has a plasma concentration 
nearly 1000-fold different compared with the concentration 
time curve for free doxorubicin. Normally, less than 1% of 
free doxorubicin actually reaches the tumor; however, with 
pegylated liposomal doxorubicin there is a 10-fold increase 
in the concentration of doxorubicin in the tumor. The peak 
uptake of the drug occurs 48–72 hours after administration, 
highlighting the stability of the delivery vehicle. The drug 
itself is released from the stealth liposomes in the interstitial 
fluid of the tumor over a period of days to weeks, thus 
exposing the tumor to a continuous drug exposure over time 
(Cattel 2003).
Rarely, nausea, vomiting, or alopecia can be seen with 
pegylated liposomal doxorubicin.
Doublet combinations
In view of the activity of pegylated liposomal doxorubicin 
with its minimal hematologic toxicity, this agent has 
been studied in numerous Phase I and II chemotherapy 
combinations involving 2 or 3 agents. 
Phase i combination studies
The Phase I doublets studied are listed in Table 3. One of the 
concerns about combination regimens is the potential to use 
subtherapeutic doses in an effort to achieve an acceptable 
regimen. One case in example is a study by Rose et al (2002) 
which was a Phase I trial of the combination of prolonged 
oral etoposide and pegylated liposomal doxorubicin. The 
study had 2 dose escalations planned: dose escalation for 
hematologic toxicity with oral etoposide followed by dose 
escalation for non-hematologic toxicity with pegylated 
liposomal doxorubicin. The starting dose of pegylated 
liposomal doxorubicin was 20 mg/m
2, followed by 50 mg/
m
2 of etoposide daily beginning on day 2. The maximum 
tolerable dose (MTD) of etoposide was found to be at 12 days. 
However, at this dose the authors were not able to increase 
the pegylated liposomal doxorubicin dose due to stomatitis 
and PPE. Five (29%) responses were noted. Of significance, 
4 of the 7 patients who progressed on this combination 
subsequently stabilized with single-agent pegylated 
liposomal doxorubicin at 40 mg/m
2 every 28 days, implying 
that the lower dose of pegylated liposomal doxorubicin was 
not a therapeutic dose in ovarian cancer.
As expected, in view of the activity of platinum compounds 
in ovarian cancer, investigators have studied the combinations 
of pegylated liposomal doxorubicin with platinum agents 
including cisplatin, carboplatin, and oxaliplatin (Lyass et 
al 2001; Goncalves et al 2003; Recchia et al 2003). Other 
investigators have studied the combinations of pegylated 
liposomal doxorubicin with taxanes, both paclitaxel and 
docetaxel (Fracasso et al 2003; Androulakis et al 2002) or 
other second-line agents such as topotecan, vinorelbine, 
and gemcitabine (Ryan et al 2000; D’Agostino et al 2003; 
Fracasso et al 2002, 2005; Tambaro et al 2003; Garcia et al 
2005; Mirchandani et al 2005; Valerio et al 2006) 
Gibbs et al (2002) and Rose et al (2000) both studied 
chemotherapy-naïve ovarian cancer patients with escalating 
pegylated liposomal doxorubicin doses with standard dose 
carboplatin area under concentration time curve (AUC) 
5 and paclitaxel at 175 mg/m
2over 3 hours. Both studies 
demonstrated the maximum tolerated dose schedule 
was carboplatin AUC 5 or 6, paclitaxel 175 mg/m
2, and 
pegylated liposomal doxorubicin 30 mg/m
2 every 28 
days. Gibbs et al (2002) found that reducing the dose of 
paclitaxel did not allow an increase in the dose of pegylated 
liposomal doxorubicin. Rose et al (2000) demonstrated that 
administering the liposomal doxorubicin every other cycle 
allowed for the maximum dose of carboplatin and paclitaxel 
to be administered. This schedule was taken forward into the 
randomized trial GOG 182-ICON 5 (Copeland et al 2003).
An alternative method of adding pegylated liposomal 
doxorubicin to the carboplatin paclitaxel regimen is by 
using the drugs sequentially rather than simultaneously. 
Potamianou et al (2005) treated patients with 4 cycles of 
carboplatin (AUC 6) and paclitaxel at 175 mg/m
2 followed 
by 4 cycles of carboplatin (AUC 6) with pegylated liposomal 
doxorubicin 40 mg/m
2 for 4 cycles. They reported a 78% 
response rate (49% complete responses and 29% partial 
responses). Seven (17%) had stable disease. The 2-year 
survival was 67%.
Phase ii combination studies
Phase II studies of pegylated liposomal doxorubicin in 
combination with various other chemotheraputic agents 
are summarized in Table 4. In platinum-sensitive recurrent 
ovarian cancer patients, doublet therapy with pegylated 
liposomal doxorubicin and carboplatin has been studied. 
The GINECO (Ferrero et al 2004) Phase II trial enrolled 
105 patients who were treated with pegylated liposomal 
doxorubicin at 30 mg/m
2 and carboplatin at an AUC of 5 on 
day 1, every 4 weeks. They observed a complete response international Journal of Nanomedicine 2006:1(3) 235
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rate of 38% and an overall response rate of 63%. The median 
progression-free survival was 9 months. Vorobiof et al (2004) 
reported a Phase II trial of pegylated liposomal doxorubicin 
(50 mg/m
2) and carboplatin at an AUC of 5 every 4 weeks. 
The overall response rate was 62.5% with a complete 
response rate of 37.5%. The median time to treatment failure 
was >287 days (range 29–819 days). 
Most of the trials have focused on platinum-resistant 
ovarian cancer patients or a mixture of platinum-sensitive 
and platinum-resistant patients. D’Agostino et al (2003) 
presented one of the first Phase II trials involving pegylated 
liposomal doxorubicin and gemcitabine in combination for 
recurrent ovarian cancer. The authors treated 67 evaluable 
patients who had failed at least one platinum and paclitaxel 
chemotherapy regimen with 30 mg/m
2 pegylated liposomal 
doxorubicin on day 1 and 1000 mg/m
2 gemcitabine on day 
1 and day 8 every 21 days. There were 7 complete responses 
(10.4%) and 16 partial responses (23.9%) as well as 26 
cases (38.8%) classified as stable disease. Among the 36 
platinum-resistant patients there were 9 (25%) responses (8 
Table 3  Phase i combinations
Author  Year  Drug (dose)  MTD
Doublets	 	 	
ryan   2000  PLD 
aPLD 20 mg/m
2 day 1
    topotecan  topotecan 1.0 mg/m
2 day 1–5
Lyass   2001  PLD  PLD 50 mg/m
2 day 1
    cisplatin  cisplatin 50 mg/m
2 day 1
D’Agostino   2002  PLD  PLD 30 mg/m
2 day 1
    gemcitabine  gemcitabine (1000 mg/m
2) q day 1 and 8 every 21 days
rose   2002  PLD  PLD 20 mg/m
2 day 1
    Oral etoposide  etoposide 50 mg/m
2 daily on day 2 for 12 days
Androulakis   2002  weekly PLD  weekly PLD 10 mg/m
2
    weekly paclitaxel  weekly paclitaxel 80 mg/m
2
Fracasso   2002  PLD  PLD 20 mg/m
2 day 1,15
    gemcitabine  gemcitabine 1000 mg/m
2 day 1,15
Goncalves   2003  PLD  PLD 35 mg/m
2 day 1
    carboplatin  carboplatin AUC 5
recchia  2003  PLD  PLD 40 mg/m
2
    oxaliplatin  oxaliplatin 130 mg/m
2
Fracasso  2003  PLD  PLD 20 mg/m
2
    docetaxel  docetaxel 40 mg/m
2 day 1,15
Tambaro   2003  PLD  PLD 30 mg/m
2 day 1
    vinorelbine  vinorelbine 25 mg/m
2 day 1,8
Fracasso   2005  PLD  PLD 25 mg/m
2 day 1
    valspodar  valspodar 0.42 mg kg/h 72 hr Ci
Mirchandani   2005  PLD  PLD 40 mg/m
2 day 1
    Ci topotecan   topotecan 0.4 mg/m
2 day1–14
Triplets	 	 	
Gibbs  2002  PLD   PLD 30 mg/m
2
    carboplatin  carboplatin AUC 6
    paclitaxel  paclitaxel 175 mg/m
2 q 28 days
      or 
      PLD 20 mg/m
2 
      carboplatin AUC 5
      paclitaxel 175 mg/m
2 q 21 days
rose  2000  PLD   PLD 30 mg/m
2 q 42 days carboplatin
    carboplatin  AUC 5 q 21 days
    paclitaxel  paclitaxel 175 mg/m
2 q 21 days
a excessive toxicity seen at this dose 
Abbreviations: AUC, area under the curve; Ci, continuous infusion; MTD, maximally tolerated dose; PLD, pegylated liposomal doxorubicin. international Journal of Nanomedicine 2006:1(3) 236
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partial and 1 complete). The hematological complications 
were considerable, with 42.8% (30 patients) with grade 3/4 
complications, but only 1 patient required hospitalization 
and there were no treatment-related deaths. There were 7 
cases (10%) of grade 3 PPE. Ferrandina et al (2005) reported 
another Phase II trial using the same doses of pegylated 
liposomal doxorubicin and gemcitabine in a very similar 
recurrent ovarian cancer patient population. Of 111 patients, 
45 patients were considered platinum-sensitive and 66 were 
platinum-resistant. Among 106 evaluable patients there 
were 9 (8.5%) complete responses and 27 (25.5%) partial 
responses for an overall response rate of 34%. Another 
36 (34%) experienced stable disease (median duration of 
34 weeks). Among the platinum-resistant patients, there 
were 2 complete and 12 partial responses for an overall 
rate of 21.6%. Among the platinum-sensitive patients there 
were 7 complete and 15 partial responses for an overall 
rate of 53.7%. Toxicities of 642 administered cycles were 
reported. Grade 4 hematological toxicity, most commonly 
leucopenia, affected 20 patients (18%). A dose reduction was 
required in 26% of patients due to PPE or mucositis and 11 
patients (10%) had their chemotherapy discontinued due to 
toxicities. Subsequently, there were 2 studies that used the 
same drugs, but at lower doses. Skarlos et al (2005) reported 
on 37 platinum-resistant patients who received pegylated 
liposomal doxorubicin, 25 mg/m
2 on day 1 and gemcitabine 
650 mg/m
2 on days 1 and 8 every 28 days. There was an 
overall response rate of 22% with an additional 5.5% having 
stable disease. The median survival was 8.4 months. Again 
myelosuppression was the most common toxicity and was 
found in 35% of patients. Only 1 case of PPE and 2 cases of 
severe stomatitis were reported. Petru et al (2006) studied 31 
patients with this combination utilizing pegylated liposomal 
doxorubicin 30mg/m
2 on day 1, and gemcitabine 650 mg/m
2 
on days 1 and 8 every 28 days. They reported a 33% response 
rate and a median overall survival of 15.8 months. 
Table 4  Phase ii doublet combinations
Author  Year  Drug (dose)  n =  Responses (%)  Stable disease  Response in
            platinum resistant
D’Agostino   2003  PLD (30 mg/m
2) q day 1  70  23 (34.3%)  26 (38.8%)  25% 
    gemcitabine (1000 mg/m
2)  
    q day 1 and 8 every 21 days
Campos  2003  PLD (30 mg/m
2) q 3 wk,  40  11 (29%)  Nr  17% 
    paclitaxel (70 mg/m
2) q wk
Ferrero  2004  PLD (30 mg/m
2) q 4 wk,  105  (63%)  Nr  0% 
    carboplatin (AUC 5) q 4 wk
vorobiof  2004  PLD (50 mg/m
2) q 4 wk,  21  13 (62.5%)  5 (23%)  0% 
    Carboplatin (AUC 5) q 4 wk
Ferrandina   2005  PLD (50 mg/m
2) q 3 wk,   106  35 (34%)  38 (34%)  21% 
    gemcitabine (1000 mg/m
2) 
    q 3 wk
Kastaros  2005  PLD (30 mg/m
2) q 3 wk,   32  13 (43%)  8 (26.7%)  25% 
    vinorelbine (30 mg/m
2) q 3 wk
Skarlos   2005   PLD (25 mg/m
2) day 1,   37  8 (22%)  2 (5.5)  22% 
    gemcitabine (650 mg/m
2) day 1  
    and 8, every 28 days
Nicoletto   2006  PLD (30–35 mg/m
2), oxaliplatin   41  22 (54%)  Nr  28.6% 
    (70 mg/m
2) q 4 wk
Petru   2006  PLD (30 mg/m
2) day 1,   30  10 (33%)  Nr  10 (33%) 
    gemcitabine (650 mg/m
2) day 1  
    and 8, every 28 days 
verhaar-Langereis   2006   PLD (30 mg/m
2), topotecan   27  7 (28%)  11 (44%)  Nr 
    (1 mg/m
2) q 3 wk
valerio  2006  PLD (30 mg/m
2)  49  18 (46%)  9 (23%)  37% 
    oxaliplatin (85 mg/m
2) 
    cyclophosphamide (750 mg/m
2)
Abbreviations: Nr, not reported; PLD, pegylated liposomal doxorubicin.international Journal of Nanomedicine 2006:1(3) 237
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Campos et al (2003) studied 40 patients who received 
pegylated liposomal doxorubicin 30 mg/m
2 every 3 weeks 
with weekly paclitaxel at 70 mg/m
2 for 18 weeks. The group 
as a whole had a median platinum-free interval of 7 months, 
and 10 were classified as platinum–taxane resistant. An 
overall 29% response rate was observed with 4 complete 
responses and 7 partial responses. The median time to 
progression was 15 weeks overall. However, the median time 
to progression among the responders was 7 months. Among 
the platinum-resistant patients there was 1 complete and 3 
partial responses for an overall rate of 17%. This compares 
with a 54% (7/13) response rate among the platinum-sensitive 
patients. Sixteen (41%) experienced grade 3/4 neutropenia 
and 21 (54%) experienced grade 3/4 PPE. The PPE rate is 
higher than in many other reports, possibly suggesting that 
the combination may increase the rate of PPE.
Katsaros et al (2005) published the results of a Phase II 
Italian multicenter trial in which patients previously treated 
with taxanes and platinum were treated with pegylated 
liposomal doxorubicin 30 mg/m
2 and vinorelbine 30 mg/m
2 
on day 1 every 3 weeks. In 10 patients the order of drug 
administration was alternated for 5 patients each, and 
pharmacokinetics were calculated. Thirty-two patients 
who had received a median of 2 previous chemotherapy 
regimes were enrolled. A median of 4 cycles (range 1–9) 
were administered. There were 2 (6%) cases of grade 3 or 
4 PPE, 4 (12%) cases of grade 3 or 4 neutropenia, 1 case of 
repeated grade 3 mucositis, and 1 case of grade 3 cardiac 
toxicity. Thirty patients were evaluable for response. After 3 
cycles, there were 13 (43%) with a partial response, 8 (26.7%) 
with stable disease, and 9 (30%) patients with progressive 
disease. After 6 cycles, there were 11 (36.7%) with 
responses – 10 partial and 1 complete, 3 (10%) with stable 
disease, and 16 cases of progressive disease (53.5%). The 
overall median survival was 9 months. There was a similar 
frequency of response in platinum-sensitive and platinum-
resistant patients. The pharmacokinetics demonstrated that 
administering pegylated liposomal doxorubicin first resulted 
in a significantly larger AUC for both drugs (p=0.0079), 
without increased toxicity. This combination produced fewer 
side-effects than previously studied combinations, suggesting 
that further study might be warranted.
Recently, Nicoleto et al (2006) published a trial of 
pegylated liposomal doxorubicin, dosed between 30 and 
35 mg/m
2 with oxaliplatin 70 mg/m
2 every 28 days. The 
overall response rate was 54%, a disease stabilization rate 
of 29% with a median survival of 22.5 months. When 
broken down by sensitivity, there was a response rate of 
66.7% among the 29 platinum-sensitive patients and 28.6% 
in the 14 platinum-resistant patients. There were 5 (12%) 
grade 3 or 4 toxicities, and only 3 patients (7%) required 
dose reduction. Neutropenia was the most common cause 
of severe toxicity. 
Verhaar-Langereis et al (2006) recently reported a trial 
of pegylated liposomal doxorubicin at 30 mg/m
2 on day 1 
followed by topotecan at 1 mg/m
2 daily for 5 days on a 21-
day cycle. Twenty-seven patients were enrolled of which 14 
of which were platinum resistant. Twenty-eight percent of 
patients responded with another 44% classified as having 
stable disease. The median time to progression was 30+ weeks 
and the overall survival was 41+ weeks. The most common 
toxicity was myelosuppression with >65% experiencing a 
grade 3 or 4 toxicity. There was 1 case of grade 4 PPE. 
While the response rates of these combinations in 
platinum-resistant ovarian cancer seem higher than reported 
with single-agent pegylated liposomal doxorubicin, a 
randomized trial is necessary to evaluate the efficacy and 
toxicity of this approach.
Conclusions
Pegylated liposomal doxorubicin is a relatively new addition 
to the armamentarium in the treatment of recurrent ovarian 
cancer. While platinum should be considered in any patient in 
whom the disease may be sensitive, eventually most patients 
progress on treatment. Pegylated liposomal doxorubicin 
should be tried in the patient with recurrent disease at some 
point in the disease course. When used as a single agent, the 
incidence of response is similar to that with other drugs, and 
varies depending on the platinum-free interval. However, in 
addition to the number of patients with disease response, 
approximately twice as many will have stable disease and 
benefit from therapy with pegylated liposomal doxorubicin. 
In the patient who is not obstructed and has a good quality of 
life, yet has measurable disease, disease stabilization may be 
an acceptable outcome. Cesano et al (1999) evaluated patients 
randomized to topotecan or paclitaxel as second-line therapy 
for ovarian cancer. Patients who achieved a partial response 
had a very similar survival to patients with stable disease. 
Gronlund et al (2004) studied 100 recurrent ovarian cancer 
patients treated with topotecan or paclitaxel and carboplatin. 
This study demonstrated a survival benefit in patients with 
stable disease compared with those with progressive disease. 
It appears that a dose of 40 mg/m
2 given every 28 days is the 
optimal dose to balance efficacy and side-effects. It should 
be emphasized that most reports show a median time to 
response of 8 weeks. The clinician must counsel the patient international Journal of Nanomedicine 2006:1(3) 238
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not to be discouraged if tumor markers progress during the 
first 2–3 cycles. 
The low rate of severe neutropenia makes pegylated 
liposomal doxorubicin an ideal drug in patients who have 
received multiple courses of chemotherapy and possibly, even 
radiation. The lack of bone marrow suppression by this drug 
makes it easier to administer to patients who have been heavily 
pretreated. However, Lorusso et al’s (2004) data actually seem 
to suggest that pegylated liposomal doxorubicin should be 
used earlier in the course of treatment to derive maximal 
benefit. There are two major avenues of ongoing research. 
The first is the continued use of this drug in combination 
with other drugs in recurrent disease. As discussed above 
there are some promising combinations that warrant further 
investigation. The second is in its incorporation into primary 
therapy in the form of triplet combinations or sequential 
doublets or maintenance therapy. Success in either of these 
areas may lead to an even more prominent role for this novel 
delivery system of doxorubicin. 
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